Systemic lupus erythematosus, or lupus, is a complex autoimmune disease in which the immune system mistakenly attacks healthy ...
The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of ...
Lupus is an autoimmune disease where the body’s immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new ...
Patients whose autoimmune disorders such as lupus were initially dismissed by doctors as psychosomatic show long-lasting ...
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal ...
HealthDay on MSN3d
Pericarditis Recurrence Occurs in About 20% of Patients With LupusFor patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20% of patients and associated factors include younger age, prednisone treatment, ...
Uniklinikum Erlangen at Friedrich-Alexander-Universität Erlangen-Nürnberg has successfully treated more than 45 people with autoimmune diseases using ...
Medpage Today on MSN13d
Frequent Healthcare Visits Seen as Early Flag for LupusComparing 2,022 lupus patients with 20,019 people from the general population, incidence rate ratios for general practice (GP ...
Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment ...
“The FDA’s sBLA acceptance for Gazyva recognizes the need to provide a more effective treatment option for people living with this devastating disease.” “Lupus nephritis is a debilitating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback